{
    "nct_id": "NCT05438420",
    "official_title": "A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors",
    "inclusion_criteria": "* The participant (or legally acceptable representative if applicable) provides written informed consent for the trial.\n* Subjects with histologically or cytologically confirmed advanced or metastatic esophageal, gastric/GEJ, hepatocellular and cervical cancers who have progressed on treatment with an anti-PD1 or anti PD-L1 monoclonal antibody (mAb) administered either as monotherapy, or in combination with other therapies\n* Have measurable disease per RECIST v 1.1. as assessed by local site investigator/radiology\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Life expectancy of at least 3 months\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* A WOCBP who has a positive urine pregnancy test (within 72 hours) prior to treatment or breast-feeding women\n* Concomitant use of strong inhibitors and inducers of CYP1A2, 2J2, 2C19, 2D6, and 3A4/5 within the timeline duration of five half-lives prior to starting study drug and throughout the trial\n* Concomitant use of sensitive substrates of CYP2C9, 2C19, and 3A4 within the timeline duration of five half-lives prior to starting study drug and throughout the trial\n* Has received prior radiotherapy within 2 weeks of start of study treatment or have had a history of radiation pneumonitis\n* Has had an allogeneic tissue/solid organ transplant",
    "miscellaneous_criteria": ""
}